MILabs Super Cluster Collimator
Turning complex radionuclides into confident decisions
Challenging radionuclides at true preclinical dose levels
The MILabs Super Cluster Collimator (SC) transforms, low-signal theranostic radionuclides into quantifiable preclinical insight.
By combining ultra-high sensitivity, preserved spatial resolution, and simultaneous multi-photopeak detection, the SC enables imaging of low and high-energy isotopes that were previously considered impractical or impossible for realistic in vivo studies. This is not just visualization. This is decision-grade theranostic data.
Want to know more?
Contact us for more information about the MILabs Super Cluster Collimator.
The Super Cluster Collimator
With the MILabs Super Cluster Collimator you’ll benefit from:
- EStudy theranostics the way they are actually administered
- EHigh sensitivity & true spatial precision
- EGain insight into both efficacy and safety in one workflow
- EFrom imaging to informed development decisions
- ERedefine what is possible in preclinical isotope research
Realistic low-dose in vivo imaging
Image Ac-225, At-211 and other challenging radionuclides at administered activities consistent with true preclinical theranostic dosing.
Super Cluster Collimator key benefits
Study theranostics the way they are actually administered.
Ultra-high sensitivity without sacrificing resolution.
See weak alpha-emitter signals clearly and know exactly where they are.
The Super Cluster Collimator delivers approximately 17 % sensitivity while maintaining spatial resolution of approximately 1.1–1.3 mm, even at high gamma energies. This enables detection of weak signals without compromising spatial accuracy, ensuring reliable localization and quantification of therapeutic agents.
High sensitivity. True spatial precision. No trade-offs.
Simultaneous imaging of multiple daughters in the decay chain.
Understand more than just where the parent isotope goes.
The system supports simultaneous imaging of multiple photopeaks within the Ac-225 decay chain, including isotopes such as Fr-221 and Bi-213. This allows researchers to evaluate therapeutic targeting alongside redistribution and potential toxicity patterns within a single study.
Gain insight into both efficacy and safety in one workflow.
Designed for true theranostic development.
Use imaging as a decision-making tool, not just a visualization step. The Super Cluster Collimator is purpose-built for theranostic workflows.
It combines:
- EUltra-high sensitivity
- EMulti-isotope capability
- ECompatibility with low-dose in vivo studies
- ESuitable for low-energy up-to high-energy of 1 MeV
This enables direct evaluation of dose distribution, targeting accuracy, and therapeutic performance within development programs.
From imaging to informed development decisions.
Expanding the feasible isotope space.
Work with the isotope you want, not just the one you can image.
The Super Cluster Collimator expands the range of radionuclides that can be realistically studied in vivo. Isotopes, once considered impractical for preclinical imaging, have become viable research tools, supporting innovation in alpha-theranostics and next-generation radiopharmaceutical development.
Redefine what is possible in preclinical isotope research.
Competitive advantage in alpha-theranostics programs.
Differentiate your research or development program in a rapidly advancing field.
For institutions and companies active in targeted alpha therapy (TAT), the Super Cluster Collimator provides a measurable technological edge. It enables confident development of Ac-225-based therapies and other high-energy radionuclides under realistic experimental conditions. This capability has already been demonstrated in live animal studies and presented to the scientific community.
Work with the isotope you want, not just the one you can image.
Download the technical details below and find out if the Super Cluster Collimator is the solution for you.
Proven capability. Strategic advantage.
Supportive evidence.
Comparison of imaging performance at 218 keV and 440 keV photopeaks demonstrates the ability to detect and localize high-energy gamma emissions from Ac-225 decay products with preserved spatial resolution.
